Pay in 4 interest-free payments of $10.50 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
PubMed Central PMCID: PMC5083757
Fenretinide (4-HPR) exerts not just acute but also long term antitumor activity in selected T-ALL cell lines
Ishikawa tumors have higher apoptotic indices than Hec1A tumors after treatment with GSK2256098
NSC-669364
Storage Condition: Powder: 4oC for 1year
PAI-039 - CAS# 393105-53-8 size:2mg solid PubMed Central PMCID: PMC5083757PAI 039, CAS No. 393105 53 8, is a novel plasminogen activator inhibitor 1 (PAI 1) inhibitor. The pharmacokinetic profile of PAI 039 indicated an oral bioavailability of 43 + 15. 3% and a plasma half life of 6. 2 + 1. 3 h. PAI 039 is an orally active prothrombolytic drug that inhibits PAI 1 and accelerates fibrinolysis while maintaining normal coagulation in a model of coronary occlusion . PAI 039 exerts antithrombotic efficacy in rat models of